Tema ETFs LLC Increases Stock Position in Stryker Corporation $SYK

Tema ETFs LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 31.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,306 shares of the medical technology company’s stock after purchasing an additional 1,743 shares during the quarter. Tema ETFs LLC’s holdings in Stryker were worth $2,300,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in SYK. Dagco Inc. raised its position in shares of Stryker by 24.0% during the 2nd quarter. Dagco Inc. now owns 1,133 shares of the medical technology company’s stock valued at $357,000 after buying an additional 219 shares in the last quarter. Lederer & Associates Investment Counsel CA grew its position in Stryker by 8.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 5,398 shares of the medical technology company’s stock worth $1,700,000 after acquiring an additional 442 shares in the last quarter. E. Ohman J or Asset Management AB increased its stake in Stryker by 1,008.0% in the second quarter. E. Ohman J or Asset Management AB now owns 131,471 shares of the medical technology company’s stock valued at $41,392,000 after acquiring an additional 119,605 shares during the last quarter. LVM Capital Management Ltd. MI increased its stake in Stryker by 15.9% in the second quarter. LVM Capital Management Ltd. MI now owns 62,584 shares of the medical technology company’s stock valued at $19,704,000 after acquiring an additional 8,576 shares during the last quarter. Finally, Fulton Bank N.A. raised its position in Stryker by 21.9% during the second quarter. Fulton Bank N.A. now owns 6,498 shares of the medical technology company’s stock valued at $2,046,000 after purchasing an additional 1,166 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SYK shares. Truist Financial lifted their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Down 0.3%

Shares of NYSE:SYK opened at $347.15 on Thursday. The stock has a market capitalization of $133.16 billion, a P/E ratio of 35.97, a price-to-earnings-growth ratio of 2.22 and a beta of 0.76. The stock’s 50-day moving average price is $323.14 and its 200-day moving average price is $333.62. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.